An interventional study of HEPA filtration and Sham filtration in Air Pollution and Atherosclerosis, sponsored by University of Southern California. Recruiting at 1 site in United States. Open to participants aged 65 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by University of Southern California · Not applicable, Interventional, and Prevention
Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.
Among the 468 studies in Atherosclerosis with a site in United States, this one is the 167th largest by planned enrollment of the 328 interventional ones that give a count, is one of 12 that started in 2023, is one of 103 with no phase, reaches primary completion later than 51 of the 70 other live ones, and was the 415th registered.
1,517 studies on the registry are indexed under Atherosclerosis; 224 are open to participants now.
Browse Atherosclerosis studies →47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 55+
Verve Therapeutics, Inc. · Sites in United States
Ages 18–70
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Argentina, Japan and 1 more country
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.
This study: 65 Years to 84 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
468 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 84 · Phase 3 74 · Phase 4 45
First in 1973; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 112 is above the median of 100 across 879 interventional studies indexed under Atherosclerosis.
Median enrollment 119 across the 328 interventional studies, 170 across the 137 observational. Of the 366 that completed or were terminated, 134 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 468 have an industry lead sponsor. The 10 most frequent:
University of Southern California is the lead sponsor of 792 studies on the registry; 137 are open to participants now.
Of its 70 completed or terminated interventional studies of FDA-regulated products, 32 (46%) have results posted.
University of Southern California has 7 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
23 of the studies in Atherosclerosis with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07121010University of PittsburghHow Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 468 studies in Atherosclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.
This double-blind, randomized, crossover trial will recruit 112 adults with ischemic heart disease history and will investigate potential benefits of indoor high efficiency particulate air (HEPA) filtration on ameliorating the progression of atherothrombosis. Participants will be contacted and recruited to the study based on inclusion and exclusion criteria. After consenting, participants will go through a total of 21-month study period comprised of true HEPA filtration and sham filtration, each of 9-month in duration, and a 3-month wash-out period. After 3-month wash-out period, participants will be switched to the other arm of the intervention. During the trial, project specialists will complete a series of home visits before, in the middle, and after each intervention session to set up air purifiers and indoor and outdoor air pollution monitors, as well as conduct interview to collect questionnaire data, measure vascular function, blood pressure, and collect biospecimens. Participants will self-monitor their daily blood pressure through out the intervention periods. In aim 1, researchers will assess the effect of a 9-month residential HEPA intervention on atherothrombosis progression in 112 participants. In aim 2, the researchers will examine the association between reduction in indoor PM2.5 exposure brought by the intervention and the changes in atherothrombosis progression indicators adjusting for outdoor PM2.5 exposure. In aim 3, researchers will examine atherothrombosis responses (both levels and slopes of change) to the HEPA intervention within four subgroups of participants: 1) non-Hispanics, 2) Hispanics, 3) females, and 4) males.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group of participants will be assigned to the intervention of HEPA filtration with the capacity to reduce indoor PM2.5 levels at their residence for 9 months first. After 3-month wash-out period, participants will be assigned to sham filters (air purifier has the same appearance but HEPA filter is removed) for 9 months.
Device: HEPA filtration · Device: Sham filtration
This group of participants will be assigned to the intervention of sham filtration with HEPA filter removed at their residence for 9 months first. After 3-month wash-out period, participants will be assigned to the HEPA filtration for 9 months.
Device: HEPA filtration · Device: Sham filtration
HEPA filters with the capacity to reduce PM2.5 levels
Sham filtration use the same appearance of air purifier but with HEPA filter removed.
Change in blood pressure
Differences between baseline and systolic and diastolic blood pressure measured during and after intervention
Time frame: Blood pressure will be monitored daily during each of the 9-month intervention
Change in carotid-femoral pulse wave velocity
Differences between baseline and carotid-femoral pulse wave velocity measured with Vicorder device during and after intervention
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Change in augmentation index
Differences between baseline and augmentation index measured with Vicorder device during and after intervention
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Change in von Willebrand factor
Differences between baseline and von Willebrand factor measured during and after intervention
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Change in P-selectin
Differences between baseline and P-selectin measured during and after intervention
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Change in fasting glucose
Differences between baseline and fasting glucose measured during and after intervention
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Change in fasting insulin
Differences between baseline and fasting insulin measured during and after intervention
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Changes in lipid profiles
Differences between baseline and low-density lipoprotein, high-density lipoprotein, very-low-density lipoprotein, triglycerides, and total cholesterol levels measured during and after intervention
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Change in C-reactive protein
Differences between baseline and C-reactive protein measured during and after intervention
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Change in interleukin 6
Differences between baseline and interleukin 6 measured during and after intervention
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Changes in 384 kinds of targeted cardiovascular disease-related proteomic markers
Differences between baseline and the relative abundance of 384 kinds of targeted cardiovascular disease-related proteomic markers, such as tumor necrosis factor, E-selectin, intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and leptin, measured with Olink's Explore 384 cardiometabolic panel 1 during and after intervention. The Olink kit is a relative quantification assay and there are no units for the measurements.
Time frame: At the baseline, in the middle (4.5 month after intervention) and immediately after each of the 9-month interventions
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jun 2028, 59 months after the start.
Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 59 months is above that.
Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Southern California →